The results are EPIC¹

Groundbreaking results of the EPIC (Evaluation of Pimobendan In dogs with Cardiomegaly) Study, the largest veterinary cardiology study in history, are now published.

15-month delay

in time to composite primary endpoint compared with dogs receiving placebo*

60%more time

in asymptomatic stage B2
of heart disease*

10% more life

without CHF signs that impact quality of life or
cardiac-related death^†

PROVEN BENEFITS OF EARLY TREATMENT OF MYXOMATOUS MITRAL VALVE DISEASE (MMVD)—BEFORE CONGESTIVE HEART FAILURE (CHF)¹

The EPIC Study showed a significant benefit in administering pimobendan in dogs with preclinical myxomatous mitral valve disease (MMVD)—before the onset of congestive heart failure (CHF) cardiac-related death, or euthanasia (composite primary endpoint).

View Findings

WHAT DOES THE EPIC STUDY MEAN FOR VETERINARIANS?

Discover how veterinarians can apply the findings of the EPIC Study to their clinical practice.

LEARN WHY THE EPIC STUDY IS SO IMPORTANT

HEAR FROM THE INVESTIGATORS

The EPIC Study represents a significant advancement in canine cardiology.
Watch the lead investigators discuss the implications of this groundbreaking study.